Blauvelt, A., Rich, P., Sofen, H., Lambert, J., Merola, J.F., Lebwohl, M., Scharnitz, T., Hoyt, K., Kisa, R.M. and Banerjee, S. 2022. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s49. DOI:https://doi.org/10.25251/skin.6.supp.49.